Efficacy and safety of emerging immunomodulatory agents versus standard therapies in refractory cutaneous lupus: A systematic review
Dermatology Online Journal · 09.05.2026 · 32 (2)
DOI: 10.25251/52gar039 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Dermatology Online Journal, online erschienen am 09.05.2026. Verfasst von Francisco Javier Gómez Ballesta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Universidad Autónoma de Bucaramanga, Colombia. Hauptthemen laut MEDLINE: Lupus Erythematosus, Cutaneous, Immunomodulating Agents, Immunologic Factors. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Refractory cutaneous lupus (RCL) remains challenging to treat, with limited response to standard therapies. Emerging immunomodulatory agents, including thalidomide, lenalidomide, anifrolumab, belimumab, and intravenous immunoglobulin, may offer improved outcomes.
Methods
A systematic review was conducted following PRISMA guidelines. Randomized controlled trials evaluating the efficacy and safety of the specified agents in adults with RCL were included. Databases searched included MEDLINE, Embase, and LILACS. Primary outcomes were CLASI, BICLA, and SRI‑4 response rates. Secondary outcomes included adverse events and quality of life.
Results
Anifrolumab achieved CLASI‑50 in up to 63.0% of patients versus 30.8% with placebo and BICLA response in up to 53.5% versus 25.7%. Belimumab improved SRI‑4 response to 43.2% versus 33.5% with placebo. RSLV‑132 and tofacitinib demonstrated partial efficacy. Herpes zoster was more frequent with anifrolumab.
Conclusion
Anifrolumab and belimumab provide superior efficacy with acceptable safety in RCL, supporting their inclusion in personalized treatment algorithms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Universidad Autónoma de Bucaramanga, Colombia.
- Faculty of Medicine, Universidad de Sucre, Bogotá D.C., Colombia.
- Faculty of Medicine, Unidad Central del Valle del Cauca (UCEVA), Tuluá, Valle del Cauca, Colombia.
- Faculty of Medicine, Universidad Juan N. Corpas, Bogotá DC, Colombia.
- Faculty of Medicine, Universidad Nacional de Colombia, Bogotá DC, Colombia.
Zitieren
APA
Gómez Ballesta, F. J., Paternina Álvarez, M. C., Betancourt Benítez, A. I., Montiel Salas, M. J., López Bermúdez, S. A., & Alzate Granados, J. P. (2026). Efficacy and safety of emerging immunomodulatory agents versus standard therapies in refractory cutaneous lupus: A systematic review. Dermatology Online Journal, 32(2). https://doi.org/10.25251/52gar039
Vancouver
Gómez Ballesta FJ, Paternina Álvarez MC, Betancourt Benítez AI, Montiel Salas MJ, López Bermúdez SA, Alzate Granados JP. Efficacy and safety of emerging immunomodulatory agents versus standard therapies in refractory cutaneous lupus: A systematic review. Dermatology Online Journal. 2026;32(2). doi:10.25251/52gar039
BibTeX
@article{GmezBallesta2026,
author = {Gómez Ballesta, Francisco Javier and Paternina Álvarez, Mariel Cecilia and Betancourt Benítez, Ana Isabel and Montiel Salas, María José and López Bermúdez, Sergio Armando and Alzate Granados, Juan Pablo},
title = {Efficacy and safety of emerging immunomodulatory agents versus standard therapies in refractory cutaneous lupus: A systematic review},
journal = {Dermatology Online Journal},
year = {2026},
volume = {32},
number = {2},
doi = {10.25251/52gar039}
}
EUVIMED